We are live on ! Find out more
AL

Aspiriant LLC Portfolio holdings

AUM $3.51B
1-Year Est. Return 13.98%
This Fund
S&P 500
This Quarter Est. Return
-3.79%
1 Year Est. Return
+13.98%
3 Year Est. Return
+39.43%
5 Year Est. Return
+43.32%
10 Year Est. Return
+133.07%
AUM
$748M
AUM Growth
+$31.6M
Cap. Flow
+$70M
Cap. Flow %
9.36%
Top 10 Hldgs %
80.99%
Holding
102
New
24
Increased
28
Reduced
30
Closed
12
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WEN icon
101
Wendy's
WEN
$1.48B
-64,196
Closed -$530K
IMPV
102
DELISTED
Imperva, Inc.
IMPV
-17,500
Closed -$503K

Similar funds

Aspiriant LLC's Q4 2014 Portfolio in Review

As of Q4 2014, Aspiriant LLC held 102 positions worth $748M, up 4.4% from $716M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Aspiriant LLC deployed $70M of net new capital in Q4 2014, opening 24 new positions and adding to 28 existing holdings. Its largest new stake was iShares MSCI EAFE Growth ETF: 147,414 shares worth $9.7M.

By sector, the portfolio is most concentrated in Financials at 6.2% of assets, down from 7% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was GS Connect S&P GSCI Enhanced Commodity Total Return Strategy Index ETN (maturity subject to postpone, an estimated $27.7M trimmed.

  • Aspiriant LLC's largest Q4 2014 buy was iShares MSCI EAFE Growth ETF: 147,414 shares worth $9.7M.
  • Aspiriant LLC added most to UBS E-TRACS Alerian MLP Infrastructure ETN in Q4 2014, an estimated $38M increase.
  • Aspiriant LLC's biggest Q4 2014 reduction was GS Connect S&P GSCI Enhanced Commodity Total Return Strategy Index ETN (maturity subject to postpone, cutting an estimated $27.7M.
  • Aspiriant LLC fully exited iShares Floating Rate Bond ETF in Q4 2014, selling an estimated $548K.
  • Aspiriant LLC's ten largest holdings make up 81% of its $748M portfolio in Q4 2014.
  • Aspiriant LLC opened 24 new positions and closed 12 in Q4 2014.
  • Aspiriant LLC's portfolio value rose 4.4% quarter-over-quarter to $748M.

Based on Aspiriant LLC's 13F filing for Q4 2014, filed 13 Feb 2015.